07:00 , Oct 7, 2013 |  BioCentury  |  Finance

4Q Financial Markets Preview: Totally baked

The fourth quarter will see buysiders focused on news in cancer and HCV from big clinical meetings and expected PDUFA decisions, as well as several large cap commercial launches. But investors warned some milestones are...
07:00 , Jun 18, 2012 |  BioCentury  |  Emerging Company Profile

Armour: Relaxin in CRPC

Armour Therapeutics Inc.'s relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway could...
08:00 , Nov 3, 2008 |  BC Week In Review  |  Clinical News

DnaJP1: Additional Phase II data

Adeona presented subset data from a double-blind Phase II trial in 160 patients that previously missed the primary endpoint of a significant improvement in ACR20 responses vs. placebo. The subset data showed that patients who...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Company News

Pipex, University of California deal

Pipex received an exclusive, worldwide license from the university to develop and commercialize oral dnaJP1 (formerly AT-001) for autoimmune diseases. Pipex said Androclus Therapeutics (San Diego, Calif.), which had been developing the compound, returned...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Clinical News

DnaJP1: Phase II data

In a double-blind, placebo-controlled, U.S. Phase II trial in 160 patients, AT-001 missed the primary endpoint of AUC of ACR20 response rates at days 112, 140 and 168 (p=0.099). A post hoc analysis showed that...
08:00 , Nov 7, 2005 |  BioCentury  |  Product Development

Reviving oral tolerance

Autoimmune startup Androclus Therapeutics aims to rekindle interest in oral tolerance therapies with its AT-001 dnaJP1 peptide against proinflammatory proteins in rheumatoid arthritis. Although AT-001 missed its target using an unconventional primary endpoint in a...
02:58 , Nov 3, 2005 |  BC Extra  |  Clinical News

Androclus' AT-001 fails RA Phase II

Androclus (San Diego, Calif.) said oral AT-001 missed the primary endpoint of under the curve of ACR20 response rates at days 112, 140 and 168 in a double-blind, placebo-controlled, U.S. Phase II trial to treat...